Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Before starting GLP-1 medications: Ensure you've had a recent diabetic eye screening (within the past 12 months) Discuss your retinopathy status with your prescribing clinician If you have known retinopathy, consider ophthalmology review before initiation Understand that gradual dose titration may help avoid very rapid changes in blood glucose, which is a general principle in diabetes management During treatment: Attend all scheduled diabetic eye screening appointments without fail If you have pre-existing retinopathy, your diabetes team may consider more frequent monitoring based on your individual clinical situation Control blood pressure to target levels (below 140/90 mmHg, or below 130/80 mmHg if you have kidney, eye or cerebrovascular damage, if tolerated) [13] Maintain good overall glycaemic control whilst avoiding excessively rapid HbA1c reductions when possible Stop smoking if applicable, as tobacco significantly worsens diabetic eye disease Manage cholesterol levels according to NICE guidance for cardiovascular risk reduction Communicate openly with your healthcare team about any visual symptoms, even if they seem minor
Even more important, the warning comes from the FDA, not the manufacturer
This log serves two purposes
Medicare Part D Claims for GLP-1s (CY 2018 to 2022) The expanded indication for Wegovy is expected to increase spending on this medication class
US$ 29.50
US$ 23.06
US$ 25.95
US$ 24.27
